Lung Cancer
Conference Coverage
Death rates ‘remain high’ in patients with thoracic cancers and COVID-19
The risk of death was similar across racial and ethnic groups.
Conference Coverage
Nivolumab improves survival in relapsed mesothelioma
Nivolumab prolonged progression-free and overall survival, compared with placebo.
Conference Coverage
Screening for lung cancer in never-smokers is ‘feasible’
Never-smokers should be screened for lung cancer too, researchers say.
News from the FDA/CDC
FDA grants MET inhibitor tepotinib accelerated approval for NSCLC
Tepotinib is the first once-daily oral MET inhibitor approved for this patient population.
Conference Coverage
‘Astonishing’ 4-year survival in NSCLC with pembro plus chemo
New data showing a doubling in survival with the combination versus chemo alone have been hailed as “very impressive” by clinicians.
Conference Coverage
Pandemic seems to impact lung cancer diagnosis and prognosis
There was a 38% decrease in new lung cancer diagnoses during the pandemic, and 30-day mortality rates nearly doubled.
Conference Coverage
AI can identify biomarkers and potentially guide therapy in NSCLC
Deep learning models accurately predicted PD-L1 positivity and EGFR mutational status in patients with non–small cell lung cancer.
From the Journals
Lung disease raises mortality risk in older RA patients
Presence of RA-associated interstitial lung disease was associated with increased total, respiratory, and cancer mortality.
From the Journals
Lung cancer screening during pandemic: Paused, then rebounded across patient subgroups
An analysis finds similar declines and rebounds in screening among Whites and non-Whites.
From the Journals
Many ED visits may be preventable for NSCLC patients
Overall, 24% of ED visits were deemed preventable, and 10% were considered unnecessary.